Lead exposure increases blood pressure by increasing angiotensinogen expression

Journal of Environmental Science and Health. Part A, Toxic/hazardous Substances & Environmental Engineering
Jiandong JiaoChunping Li

Abstract

Lead exposure can induce increased blood pressure. Several mechanisms have been proposed to explain lead-induced hypertension. Changes in angiotensinogen (AGT) expression levels or gene variants may also influence blood pressure. In this study, we hypothesized that AGT expression levels or gene variants contribute to lead-induced hypertension. A preliminary HEK293 cell model experiment was performed to analyze the association between AGT expression and lead exposure. In a population-based study, serum AGT level was measured in both lead-exposed and control populations. To further detect the influence of AGT gene single nucleotide polymorphisms (SNPs) in lead-induced hypertension, two SNPs (rs699 and rs4762) were genotyped in a case-control study including 219 lead-exposed subjects and 393 controls. Lead exposure caused an increase in AGT expression level in HEK 293 cell models (P < 0.001) compared to lead-free cells, and individuals exposed to lead had higher systolic and diastolic blood pressure (P < 0.001). Lead-exposed individuals had higher serum AGT levels compared to controls (P < 0.001). However, no association was found between AGT gene SNPs (rs699 and rs4762) and lead exposure. Nevertheless, the change in AGT expressio...Continue Reading

References

Oct 2, 1992·Cell·X JeunemaitreJ M Lalouel
Mar 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·H S KimO Smithies
Jun 1, 1993·Circulation·K K GriendlingR W Alexander
Jan 14, 1999·Journal of Hypertension·F C Luft
Mar 4, 2000·Environmental Health Perspectives·A O Onalaja, L Claudio
Oct 6, 2001·American Journal of Hypertension·S A Shelkovnikov, H C Gonick
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Dec 25, 2002·Epidemiology·Barbara S GlennBrian S Schwartz
Jan 4, 2003·Hypertension·Alexandre C PereiraJosé E Krieger
Apr 14, 2007·Environmental Health Perspectives·Howard HuBrian S Schwartz
Apr 14, 2007·Environmental Health Perspectives·Ana Navas-AcienStephen J Rothenberg
Feb 1, 2008·Toxicological Sciences : an Official Journal of the Society of Toxicology·Larissa Tercilia Grizzo, Sandra Cordellini
Jun 24, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Nosratola D Vaziri
Apr 16, 2011·PloS One·Maylla Ronacher SimõesMirian Fioresi
Dec 20, 2012·Experimental and Therapeutic Medicine·Hyun-Kyung ParkDae Jean Jo
Oct 26, 2013·Toxicology Mechanisms and Methods·Chunping LiNa Sun
Jul 18, 2014·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Hyung-Ki KimHak-Jae Kim

❮ Previous
Next ❯

Citations

May 24, 2019·Human & Experimental Toxicology·M S ManiH S Dsouza
Apr 12, 2021·Environmental Science and Pollution Research International·Zihan ChenXijin Xu

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
atomic absorption spectrometry
genotyping
ELISA

Software Mentioned

SAS

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.